R
Ramesh Padmanabha
Researcher at Bristol-Myers Squibb
Publications - 29
Citations - 1023
Ramesh Padmanabha is an academic researcher from Bristol-Myers Squibb. The author has contributed to research in topics: Phospholipase & Non-competitive inhibition. The author has an hindex of 13, co-authored 28 publications receiving 968 citations.
Papers
More filters
Journal ArticleDOI
2-aminothiazole as a novel kinase inhibitor template. Structure-activity relationship studies toward the discovery of N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1- piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide (dasatinib, BMS-354825) as a potent pan-Src kinase inhibitor.
Jagabandhu Das,Ping Chen,Derek J. Norris,Ramesh Padmanabha,James Lin,Robert V. Moquin,Zhongqi Shen,Lynda S. Cook,Arthur M. Doweyko,Sidney Pitt,Suhong Pang,Ding Ren Shen,Qiong Fang,Henry F. De Fex,Kim W. McIntyre,David J. Shuster,Kathleen M. Gillooly,Kamelia Behnia,Gary L. Schieven,John Wityak,Joel C. Barrish +20 more
TL;DR: Molecular modeling was used to construct a putative binding model for Lck inhibition by Dasatinib and 12m, and the framework of key hydrogen-bond interactions proposed was in agreement with the subsequent, published crystal structure of 2 bound to structurally similar Abl kinase.
Patent
Cyclic protein tyrosine kinase inhibitors
Jagabandhu Das,Ramesh Padmanabha,Ping Chen,Derek J. Norris,Arthur M. Doweyko,Joel C. Barrish,John Wityak +6 more
TL;DR: In this paper, novel cyclic compounds and salts thereof, pharmaceutical compositions containing such compounds, and methods of using such compounds in the treatment of protein tyrosine kinase-associated disorders such as immunologic and oncologic disorders.
Journal ArticleDOI
2-hydroxy-N-arylbenzenesulfonamides as ATP-citrate lyase inhibitors.
James J. Li,Haixia Wang,Joseph A. Tino,Jeffrey A. Robl,Timothy F. Herpin,R. Michael Lawrence,Scott A. Biller,Jamil Haris,Randy Ponticiello,Luping Chen,Ching-Hsuen Chu,Neil Flynn,Dong Cheng,Rulin Zhao,Bang-Chi Chen,Dora M. Schnur,Mary T. Obermeier,Vito G. Sasseville,Ramesh Padmanabha,Kristen Pike,Thomas Harrity +20 more
TL;DR: A novel series of 2-hydroxy-N-arylbenzenesulfonamides were identified to be ATP-citrate lyase (ACL) inhibitors with compound 9 displaying potent in vitro activity, which lowered plasma cholesterol, triglyceride, and glucose, as well as inhibited weight gain.
Patent
Imidazoquinoxaline protein tyrosine kinase inhibitors
Joel C. Barrish,Ping Chen,Jagabandhu Das,Edwin J. Iwanowicz,Derek J. Norris,Ramesh Padmanabha,Jacques Y. Roberge,Gary L. Schieven +7 more
TL;DR: In this article, the authors present novel imidazoquinoxalines and salts thereof, pharmaceutical compositions containing such compounds, and methods of using such compounds in the treatment of protein tyrosine kinase-associated disorders such as immunologic disorders.
Journal ArticleDOI
Targeting the MraY and MurG bacterial enzymes for antimicrobial therapeutic intervention.
Laura Zawadzke,Ping Wu,Lynda S. Cook,Li Fan,Margaret Casperson,Mona Kishnani,Deepa Calambur,Hofstead Sandra J,Ramesh Padmanabha +8 more
TL;DR: Assays for two enzymes from Escherichia coli were developed and validated as antibacterial inhibitor screens and several inhibitors resulting from a high-throughput screen were found and evaluated for potential therapeutic use.